Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients

Highlights • Prognostic and predictive value of RAD51 protein loss has been assesed. • Loss of RAD51 is unfavourable prognostic factor in early stage resected NSCLC. • Loss of RAD51 is favourable in patients receiving perioperative Chemo-/Radiotherapy

Saved in:
Bibliographic Details
Published inLung cancer (Amsterdam, Netherlands) Vol. 105; pp. 31 - 38
Main Authors Gachechiladze, Mariam, Škarda, Josef, Kolek, Vítězslav, Grygárková, Ivona, Langova, Katerina, Bouchal, Jan, Kolář, Zdeněk, Baty, Florent, Stahel, Rolf, Weder, Walter, Soltermann, Alex, Joerger, Markus
Format Journal Article
LanguageEnglish
Published Ireland Elsevier B.V 01.03.2017
Subjects
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Chemotherapy
DNA repair
Drug Therapy
Female
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Middle Aged
Neoplasm Staging
Non-small-cell lung cancer
Predictive Value of Tests
Prognosis
Pulmonary/Respiratory
RAD51
Rad51 Recombinase - metabolism
Radiotherapy
Thoracic Surgical Procedures
Treatment Outcome
Young Adult
RAD51
chemotherapy
DNA repair
non-small-cell lung cancer
Non-small-cell lung cancer
Chemotherapy
Online AccessGet full text

Cover

More Information
Summary:Highlights • Prognostic and predictive value of RAD51 protein loss has been assesed. • Loss of RAD51 is unfavourable prognostic factor in early stage resected NSCLC. • Loss of RAD51 is favourable in patients receiving perioperative Chemo-/Radiotherapy
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2017.01.009